These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19211649)

  • 1. Translation of basic science into clinical medicine: novel targets for diabetic nephropathy.
    Miyata T; van Ypersele de Strihou C
    Nephrol Dial Transplant; 2009 May; 24(5):1373-7. PubMed ID: 19211649
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats.
    Izuhara Y; Sada T; Yanagisawa H; Koike H; Ohtomo S; Dan T; Ito S; Nangaku M; van Ypersele de Strihou C; Miyata T
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1767-73. PubMed ID: 18658044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
    Tominaga N; Robert A; Izuhara Y; Ohtomo S; Dan T; Chihara K; Kurokawa K; Van Ypersele de Strihou C; Miyata T
    Nephrology (Carlton); 2009 Sep; 14(6):581-7. PubMed ID: 19712258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Battle against the renin-angiotensin system: help from an unexpected party.
    Müller D; Müller DN
    Nephrol Dial Transplant; 2009 Apr; 24(4):1110-2. PubMed ID: 19176687
    [No Abstract]   [Full Text] [Related]  

  • 7. Diabetic nephropathy--where next?
    Phillips AO
    QJM; 2000 Oct; 93(10):643-6. PubMed ID: 11029473
    [No Abstract]   [Full Text] [Related]  

  • 8. The kidney and the eye in people with diabetes mellitus.
    Agarwal SK; Venkatesh P; Tandon N
    Natl Med J India; 2008; 21(2):82-9. PubMed ID: 18807316
    [No Abstract]   [Full Text] [Related]  

  • 9. [Can diabetic nephropathy be prevented?].
    Groop L
    Duodecim; 1990; 106(9):695-703. PubMed ID: 1670361
    [No Abstract]   [Full Text] [Related]  

  • 10. Renal and retinal effects of enalapril and losartan in type 1 diabetes.
    Katavetin P; Katavetin P
    N Engl J Med; 2009 Oct; 361(14):1410-1; author reply 1411. PubMed ID: 19802919
    [No Abstract]   [Full Text] [Related]  

  • 11. The bumpy road to evidence: why many research findings are lost in translation.
    Lüscher TF
    Eur Heart J; 2013 Nov; 34(43):3329-35. PubMed ID: 24092246
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
    Agha A; Amer W; Anwar E; Bashir K
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):429-35. PubMed ID: 19414946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotective effects of an angiotensin II receptor blocker in experimental model rats with hypertension and metabolic disorders.
    Watanabe D; Tanabe A; Naruse M; Morikawa S; Ezaki T; Takano K
    Hypertens Res; 2009 Sep; 32(9):807-15. PubMed ID: 19662019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel mechanisms and therapeutic options in diabetic nephropathy.
    Miyata T
    Pol Arch Med Wewn; 2009 Apr; 119(4):261-4. PubMed ID: 19413187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endothelial dysfunction and diabetes: possible role in kidney damage].
    Tesauro M; Leo R; Lauro R; Cardillo C
    G Ital Nefrol; 2009; 26 Suppl 46():62-70. PubMed ID: 19644821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention strategies for diabetic nephropathy].
    Romero R
    Nefrologia; 2002; 22(3):225-7. PubMed ID: 12123121
    [No Abstract]   [Full Text] [Related]  

  • 18. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S; Sar F; Bengi-Bozkurt O; Kazancioglu R
    Kidney Blood Press Res; 2009; 32(4):268-75. PubMed ID: 19776644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diabetic nephropathy: the role of blood pressure and extra-cellular volume in its pathogenesis and treatment].
    Luik PT; Visser FW; Dullaart RP; Navis GJ
    Ned Tijdschr Geneeskd; 2004 Apr; 148(17):855-6; author reply 856. PubMed ID: 15141656
    [No Abstract]   [Full Text] [Related]  

  • 20. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes.
    Joshi D; Gupta R; Dubey A; Shiwalkar A; Pathak P; Gupta RC; Chauthaiwale V; Dutt C
    J Cardiovasc Pharmacol; 2009 Jul; 54(1):72-81. PubMed ID: 19546815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.